Melanie Kleinschek
About Melanie Kleinschek
Title: Chief Scientific Officer
Melanie Kleinschek currently holds the title of Chief Scientific Officer. In this role, she oversees scientific strategy and research direction, leveraging her extensive background in translational immunology and drug discovery. Her leadership ensures the scientific integrity and innovation within the organization.
Education and Expertise
Melanie Kleinschek holds a Doctor of Veterinary Medicine from Justus Liebig University in Giessen, Germany. Furthering her education, she earned a PhD in immunology from Leipzig University. Her expertise is rooted in immunology, with extensive postgraduate research in cytokine biology in inflammatory diseases conducted at DNAX. This academic background forms a solid foundation for her illustrious career in scientific research and leadership.
Professional Background
Melanie Kleinschek has extensive professional experience, notably in her previous roles at Theravance where she served as Vice President of Science and Innovation Strategy, leading disease area and indication strategy across inflammation and fibrosis franchises. She also held the position of VP of Biology & Pharmacology at Theravance, managing preclinical and translational biology for respiratory, gastrointestinal, skin, and ocular inflammation programs. Earlier in her career, she worked with Merck and Schering-Plough, focusing on mucosal immunology and immunoregulation in drug discovery.
Drug Discovery Experience
With 20 years of experience in drug discovery, Melanie Kleinschek has made significant contributions to the field of translational immunology. Her work spans various aspects of immunology, including mucosal immunology and immunoregulation. The breadth of her experience has equipped her with critical insights into the development of innovative therapeutic strategies.